On July 11, 2026, Prof. Lin Yiwen, Vice President of South China University of Technology (SCUT), led a delegation to Shenzhen Salubris Pharmaceuticals Co., Ltd. for an exchange visit and a meeting with distinguished alumna Ms. Liao Qingqing. The delegation included Ms. Jiang Lianxia, Director of the Office for Domestic Cooperation (Alumni Affairs Office); Mr. Mao Shanchao, Deputy Director; Prof. Huang Guoqing, Party Secretary of the School of Chemistry and Chemical Engineering; Mr. Zheng Cunhui, Division-Level Party Organization Officer; and Mr. Liu Caigang, Deputy Party Secretary of the School. Mr. Ye Chenghai, Chairman of Salubris Pharmaceuticals, together with his wife, alumna Ms. Liao Qingqing, extended a warm welcome to the SCUT delegation.
On behalf of the university, Vice President Lin Yiwen expressed sincere gratitude to Chairman Ye and Ms. Liao for their longstanding and generous support for SCUT’s development. He provided a comprehensive overview of the university’s recent progress and achievements in high-quality development, with particular emphasis on the advancement of key disciplines, the enhancement of overall institutional capacity, and the refinement of talent cultivation systems. He briefed the couple on the operation, utilization, and educational outcomes of the Liao Qingqing Alumni Fund, affirming its pivotal role in supporting student development and disciplinary advancement. He also cordially invited Chairman Ye and Ms. Liao to visit SCUT frequently and to share their entrepreneurial experiences with young students, thereby inspiring them to pursue academic excellence and personal growth.
Mr. Huang Guoqing, Party Secretary of the School of Chemistry and Chemical Engineering, expressed gratitude on behalf of the school. He reported on the tangible outcomes achieved through the Liao Qingqing Alumni Fund at the school, noting that the fund has significantly bolstered talent cultivation, upgraded laboratory research infrastructure, and provided solid support for the development of top-tier professionals and key research in chemical engineering. He also outlined the school’s current progress and major ongoing initiatives, expressing the hope for further strengthened collaboration with Salubris Pharmaceuticals.
At the corporate exhibition hall, Chairman Ye Chenghai walked the delegation through Salubris’s entrepreneurial journey and strategic development roadmap. He systematically presented the company’s R&D pipelines for innovative medicines and high-end medical devices, core product portfolios, sustained substantial investment in R&D, and its in-house independent research system. He stated that Salubris remains committed to its patient-centered mission, continuously expands healthcare services, relentlessly pursues pharmaceutical quality, fulfills its corporate social responsibility through robust technological innovation, and dedicates itself to advancing national public health.
During the forum, Chairman Ye and alumna Ms. Liao fondly recalled their student days at the South China Institute of Technology (the predecessor of SCUT), and Ms. Liao expressed her profound affection for her alma mater. The two sides reached a consensus on joint talent cultivation and collaborative industry-academia-research innovation. Both parties agreed to deepen university-industry ties by integrating theoretical learning with industrial practice, encouraging students to engage in frontline industry work and develop in alignment with market demands, and fostering two-way exchanges between academic and industrial perspectives. Leveraging the university’s strengths in fundamental research and the enterprise’s industrial translation platform, both sides will complement each other’s resources to generate high-impact research and industrial outputs that address public health needs, and to advance healthcare development through in-depth industry-academia-research integration. SCUT reaffirmed its commitment to providing quality services for its alumni. Taking the Liao Qingqing Alumni Fund as a key vehicle for cooperation, the university will further open channels for joint talent training and co-developed research projects. Salubris Pharmaceuticals looks forward to closer ties with SCUT, particularly with the School of Chemistry and Chemical Engineering, in recruiting outstanding talents majoring in chemical engineering and biomedicine, and in jointly tackling R&D challenges for new medicines and new materials technologies. The partnership aims to achieve mutual empowerment and win-win progress for both university talent cultivation and corporate innovation
This visit further strengthened the bonds between SCUT, its distinguished alumna, and a leading industrial enterprise, laying a solid foundation for collaborative talent development and deep industry-academia-research integration. Going forward, SCUT will continue to promote corporate outreach and university-enterprise engagement, pooling alumni resources to advance the integrated development of education, science and technology, and talent. Through coordinated efforts among the university, local government, and enterprises, it will contribute to the high-quality growth of the biomedicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area.
Company Profile
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (Stock Code: 002294), is an innovation-driven pharmaceutical enterprise integrating R&D, production, and sales, with operations spanning China and global markets. Focusing on chronic disease therapies to safeguard human health, the company has developed three major innovation segments: high-end chemical pharmaceuticals, biomedicines, and medical devices. It delivers comprehensive therapeutic solutions for patients worldwide with premium-grade products, rigorous evidence-based medical data, and well-rounded product portfolios. Salubris operates R&D platforms for small-molecule chemical drugs, biopharmaceuticals, siRNA and gene-editing therapeutics, as well as medical devices. It has undertaken more than 70 major national, provincial, and municipal science and technology projects during the 11th, 12th, and 13th Five-Year Plan periods. The company has won the China Patent Gold Award three times and has been honored as a National Technology Innovation Demonstration Enterprise and a Best Industrial Enterprise of China's Pharmaceutical R&D Pipeline, among other accolades.
Text & Photos: School of Chemistry and Chemical Engineering, Shenzhen Salubris Pharmaceuticals Co., Ltd.Preliminary Review: Zheng CunhuiSecondary Review: Mao ShanchaoFinal Review: Huang Guoqing